Out of the darkness and into the light: Bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma

Journal of Clinical Pathology

Volumn 63, Issue 3, 2010, Pages 210-219

  Gruver, Aaron M ^a   Peerwani, Ziad ^a   Tubbs, Raymond R ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANALYTIC METHOD; BREAST CANCER; BREAST CARCINOMA; BRIGHT FIELD IN SITU HYBRIDIZATION; CANCER PATIENT; CHROMOGENIC IN SITU HYBRIDIZATION; CLINICAL PROTOCOL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENETIC SCREENING; HUMAN; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; METALLURGY; METASTASIS; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; SILVER IN SITU HYBRIDISATION;

BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE;

EID: 77749295019     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.062760     Document Type: Review

References (88)

1. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 1953;171:737-8.
2. Tjio JH, Levan A. The chromosome number of man. Hereditas 1956;42:1-6.
3. de Jong H. Visualizing DNA domains and sequences by microscopy: a fifty-year history of molecular cytogenetics. Genome 2003;46:943- 6.
4. Schildkraut CL, Marmur J, Doty P. The formation of hybrid DNA molecules and their use in studies of DNA homologies. J Mol Biol 1961;3:595-617.
5. Gall JG, Pardue ML. Formation and detection of RNA - DNA hybrid molecules in cytological preparations. Proc Natl Acad Sci U S A 1969;63:378-83.
6. Pardue ML, Gall JG. Molecular hybridization of radioactive DNA to the DNA of cytological preparations. Proc Natl Acad Sci U S A 1969;64:600-4.
7. Buongiorno-Nardelli M, Amaldi F. Autoradiographic detection of molecular hybrids between RNA and DNA in tissue sections. Nature 1970;225:946-8.
8. John HA, Birnstiel ML, Jones KW. RNA - DNA hybrids at the cytological level. Nature 1969;223:582-7.
9. Langer-Safer PR, Levine M, Ward DC. Immunological method for mapping genes on Drosophila polytene chromosomes. Proc Natl Acad Sci U S A 1982;79:4381-5.
10. Van Prooijen-Knegt AC, Van Hoek JF, Bauman JG, et al. In situ hybridization of DNA sequences in human metaphase chromosomes visualized by an indirect fluorescent immunocytochemical procedure. Exp Cell Res 1982;141:397-407.
11. Trask BJ. Human cytogenetics: 46 chromosomes, 46 years and counting. Nat Rev Genet 2002;3:769-78.
12. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 2007;38:1105- 22.
13. Landegent JE, Jansen in de Wal N, van Ommen GJ, et al. Chromosomal localization of a unique gene by non-autoradiographic in situ hybridization. Nature 1985;317:175-7.
14. Volpi EV, Bridger JM. FISH glossary: an overview of the fluorescence in situ hybridization technique. BioTechniques 2008;45:385-6, 388, 390 passim.
15. Keen-Kim D, Nooraie F, Rao PN. Cytogenetic biomarkers for human cancer. Front Biosci 2008;13:5928-49.
16. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
17. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-87.
18. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
19. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 1988;2:273-7.
20. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
21. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
22. Madarnas Y, Trudeau M, Franek JA, et al. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 2008;34:539- 57.
23. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
24. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228-33.
25. Sikov WM, Dizon DS, Strenger R, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: A Brown University Oncology Group Study. J Clin Oncol 2009;27:4693- 700.
26. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008;14:14-24.
27. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43.
28. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
29. Dowsett M, Cooke T, Ellis I, et al. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 2000;36:170-6.
30. Elbauomy Elsheikh S, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007;9:R23.
31. Arriola E, Rodriguez-Pinilla SM, Lambros MB, et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 2007;106:181-9.
32. Rodriguez-Pinilla SM, Jones RL, Lambros MB, et al. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol 2007;60:1017-23.
33. Reis-Filho JS, Savage K, Lambros MB, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006;19:999-1009.
34. Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005;7:R1028-35.
35. Martinho O, Longatto-Filho A, Lambros MB, et al. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer 2009;101:973-82.
36. Walker F, Abramowitz L, Benabderrahmane D, et al. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum Pathol 2009;40:1517-21.
37. Scartozzi M, Bearzi I, Mandolesi A, et al. Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 2009;9:303.
38. Gaiser T, Waha A, Moessler F, et al. Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas. Mod Pathol 2009;22:1263-71.
39. Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 2005;36:250-61.
40. Tubbs RR, Stoler MH. Cell and tissue based molecular pathology: a volume in the series foundations in diagnostic pathology. Philadelphia: Churchill Livingstone Elsevier, 2009:441.
41. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467-72.
42. Vos CB, Ter Haar NT, Peterse JL, et al. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol 1999;187:279-84.
43. Davison JM, Morgan TW, His BL, et al. Subtracted, unique-sequence, in situ hybridization: experimental and diagnostic applications. Am J Pathol 1998;153:1401-9.
44. Lambros MB, Simpson PT, Jones C, et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006;86:398-408.
45. Zhao J, Wu R, Au A, et al. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 2002;15:657-65.
46. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 2002;82:1007-14.
47. Gupta D, Middleton LP, Whitaker MJ, et al. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 2003;119:381-7.
48. Park K, Kim J, Lim S, et al. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol 2003;16:937-43.
49. Arnould L, Denoux Y, MacGrogan G, et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 2003;88:1587-91.
50. Isola J, Tanner M, Forsyth A, et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004;10:4793- 8.
51. Hauser-Kronberger C, Dandachi N. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol 2004;35:647-53.
52. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? Am J Clin Pathol 2005;123:237- 43.
53. Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol 2005;18:1015-21.
54. Lin F, Shen T, Prichard JW. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens. Diagn Cytopathol 2005;33:376-80.
55. Li-Ning-T E, Ronchetti R, Torres-Cabala C, et al. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH. Int J Surg Pathol 2005;13:343-51.
56. Loring P, Cummins R, O'Grady A, et al. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl Immunohistochem Mol Morphol 2005;13:194-200.
57. Saez A, Andreu FJ, Segui MA, et al. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases. Breast 2006;15:519-27.
58. Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 2006;19:481-7.
59. van de Vijver M, Bilous M, Hanna W, et al. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res 2007;9:R68.
60. Cayre A, Mishellany F, Lagarde N, et al. Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification. Breast Cancer Res 2007;9:R64.
61. Sinczak-Kuta A, Tomaszewska R, Rudnicka-Sosin L, et al. Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods. Pol J Pathol 2007;58:41-50.
62. Di Palma S, Collins N, Faulkes C, et al. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer. J Clin Pathol 2007;60:1067-8.
63. Carbone A, Botti G, Gloghini A, et al. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn 2008;10:527-36.
64. Di Palma S, Collins N, Bilous M, et al. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer. J Clin Pathol 2008;61:757-60.
65. Pothos A, Plastira K, Plastiras A, et al. Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/neu oncogene in archival material of breast carcinoma. Acta Histochem Cytochem 2008;41:59-64.
66. Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol 2009;131:490-7.
67. Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol 2009;18:96-102.
68. Hyun CL, Lee HE, Kim KS, et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 2008;61:317-21.
69. Bartlett JM, Campbell FM, Mallon EA. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined? Am J Clin Pathol 2008;130:920-6.
70. Powell RD, Pettay JD, Powell WC, et al. Metallographic in situ hybridization. Hum Pathol 2007;38:1145-59.
71. Tubbs RR, Pettay J, Skacel M, et al. Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification. Am J Pathol 2002;160:1589-95.
72. Tubbs RR, Pettay J, Hicks D, et al. Novel bright field molecular morphology methods for detection of HER2 gene amplification. J Mol Histol 2004;35:589-94.
73. Tubbs RR, Skacel M, Pettay J, et al. Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma. Am J Surg Pathol 2002;26:908-13.
74. Patel RM, Downs-Kelly E, Weiss SW, et al. Dual-color, break-apart fluorescence in situ hybridization for EWS gene rearrangement distinguishes clear cell sarcoma of soft tissue from malignant melanoma. Mod Pathol 2005;18:1585-90.
75. Downs-Kelly E, Pettay J, Hicks D, et al. Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol 2005;29:1505-11.
76. Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007;451:19-25.
77. Shousha S, Peston D, Amo-Takyi B, et al. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 2009;54:248-53.
78. Collins N, Faulkes C, Ping B, et al. A fast, accurate and robust alternative interpretation technique for evaluation of HER2 status in breast cancer using silver in situ hybridisation (SISH). J Clin Pathol. In press.
79. Bartlett JM, Campbell FM, Ibrahim M, et al. Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH. Am J Clin Pathol 2009;132:514-20.
80. Kerstens HM, Poddighe PJ, Hanselaar AG. Double-target in situ hybridization in brightfield microscopy. J Histochem Cytochem 1994;42:1071-7.
81. Speel EJ, Jansen MP, Ramaekers FC, et al. A novel triple-color detection procedure for brightfield microscopy, combining in situ hybridization with immunocytochemistry. J Histochem Cytochem 1994;42:1299-307.
82. Hopman AH, Claessen S, Speel EJ. Multi-colour brightfield in situ hybridisation on tissue sections. Histochem Cell Biol 1997;108:291-8.
83. Laakso M, Tanner M, Isola J. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol 2006;210:3-9.
84. Shipley J. Putting the colours into chromogenic in situ hybridization (CISH). J Pathol 2006;210:1-2.
85. Mayr D, Heim S, Weyrauch K, et al. Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology 2009;55:716-3.
86. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, et al. Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH). Diagn Pathol 2008;3:41.
87. Kurosumi M. Recent trends of HER-2 testing and trastuzumab therapy for breast cancer. Breast Cancer 2009;16:283.
88. Walk EE. The role of pathologists in the era of personalized medicine. Arch Pathol Lab Med 2009;133:605-10.